MTSR
Metsera Inc
A biopharmaceutical company that develops medicines for obesity and cardiometabolic diseases, Metsera builds oral and injectable treatments like berobenatide (MET-097i), an ultra-long-acting weight-loss drug being designed for once-a-month shots. Founded in 2022 by the investment firms Population Health Partners and ARCH Venture Partners, and co-founded by Dr. Clive Meanwell, it became part of Pfizer in November 2025. Its name is a nod to "metabolic," the very field it targets.
CUSIP: 59267L107HealthcareUS1 holder